Multiprotein Silencing Using WRAP-Based Nanoparticles: A Proof of Concept
- 29 May 2025
- journal article
- Published by American Chemical Society (ACS) in Bioconjugate Chemistry
- Vol. 36 (6) , 1218-1233
Abstract
Cancer remains the leading cause of death, with chemotherapy, radiotherapy, and surgical resection being the primary treatment methods. However, chemotherapy's side effects, surgical limitations, and drug resistance present significant challenges. Small interfering RNA (siRNA) has emerged as a promising tool in cancer therapy due to its ability to silence disease-related genes selectively. Recent advancements in nonviral delivery systems, particularly cell-penetrating peptides (CPPs), have enhanced the efficacy of siRNA delivery. The use of siRNA as a therapeutic tool in cancer treatment has been reported in the literature. However, silencing only one target protein has only a minor effect on tumor cell proliferation, as previously shown for WRAP-based nanoparticles targeting cyclin-dependent kinase 4 (CDK4) in human U87 glioblastoma cells. Here, we designed a more sophisticated approach to enhance therapeutic efficacy, encapsulating multiple siRNAs targeting CDK4, cyclin D1 (CD1), and MCL-1 proteins. The siRNA cocktail, delivered via WRAP5 nanoparticles, effectively silenced these targets and reduced cell proliferation in human U87 glioblastoma cells. Furthermore, the nanoparticles also demonstrated potential therapeutic impact in gastrointestinal stromal tumors (GIST), a rare cancer characterized by its tendency to resist standard treatments. This study highlights the versatility of WRAP5 nanoparticles as a platform for personalized cancer therapy, suggesting that siRNA delivery systems may be tailored to specific cancer types for more effective treatment strategies.Keywords
Funding Information
- Agence Nationale de la Recherche (ANR-21-CE18-0022-01)
- Institut National de la Santé et de la Recherche Médicale
- Université de Montpellier
- Fondation ARC pour la Recherche sur le Cancer (PJA20171206171)
- Centre National de la Recherche Scientifique
- French Muscular Dystrophy Association (23800)
This publication has 54 references indexed in Scilit:
- Enhancing WRAP‐Based Nanoparticles for Small Interfering Ribonucleic Acid Delivery in pH‐Sensitive EnvironmentsChemMedChem, 2025
- In Situ Cocktail Nanovaccine for Cancer ImmunotherapyAdvanced Science, 2023
- Cell-Penetrating Peptides Delivering siRNAs: An Overview2021
- Deciphering the internalization mechanism of WRAP:siRNA nanoparticlesBiochimica et Biophysica Acta (BBA) - Biomembranes, 2020
- Recent advances in siRNA delivery mediated by lipid-based nanoparticlesAdvanced Drug Delivery Reviews, 2020
- Dendrimer mediated targeting of siRNA against polo‐like kinase for the treatment of triple negative breast cancerJournal of Biomedical Materials Research Part A, 2019
- Patisiran: First Global ApprovalDrugs, 2018
- Lipid nanoparticle siRNA cocktails for the treatment of mantle cell lymphomaBioengineering & Translational Medicine, 2018
- Cyclin D1, cancer progression, and opportunities in cancer treatmentJournal of Molecular Medicine, 2016
- Cytotoxicity of zinc oxide (ZnO) nanoparticles is influenced by cell density and culture formatArchives of Toxicology, 2010